Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Ozette Technologies is a life science data company that accelerates the development of therapies and diagnostics by digitizing immune data.
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints.
MOMA Therapeutics operates as a biotechnology company.
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Acrigen Biosciences is dedicated to making gene editing safe.
ENB Therapeutics develops therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents.
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
NextVivo is a biotech company developing an immune organoid technology platform.
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Industrial-scale genome sequencing
Crop Enhancement develop sustainable agrochemical formulations that employ environmentally friendly chemistry to improve crop yields.
Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.
IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune diseases.
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Recludix pharma is a developing platform to treat cancer patients.
CrossBridge Bio operates as a biotechnology company.
Eclipse Bioinnovations is an RNA genomics company that provides products and services to academic and industry customers around the world.
Alexandria Venture Investments has invested in 184 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Therapeutics, Life Science, Medical, Health Care. The firm invests across 21 different industry categories.
Among tracked funding rounds, Immunai received $215.0M in a Series B round. Alexandria Venture Investments's total known invested capital is $8.0B.
Alexandria Venture Investments's average investment size is $43.4M across its portfolio of 184 companies.
Recent Alexandria Venture Investments portfolio additions include Ozette Technologies, DEM BioPharma, MOMA Therapeutics, Cardea Bio, Pheast Therapeutics. These companies were founded in 2020 or later.